[HTML] lww.com

[HTML][HTML] Long-acting cabotegravir and rilpivirine for HIV-1 suppression: switch to 2-monthly dosing after 5 years of daily oral therapy

A Mills, GJ Richmond, C Newman, O Osiyemi, J Cade… - Aids, 2022 - journals.lww.com
Objectives: Long-acting formulations of cabotegravir (CAB) and rilpivirine (RPV) have
demonstrated efficacy in Phase 3 studies. POLAR (NCT03639311) assessed antiviral …
被引用次数：17 相关文章

Long-acting cabotegravir and rilpivirine for HIV-1 suppression: switch to 2-monthly dosing after 5 years of daily oral therapy.

A Mills, GJ Richmond, C Newman, O Osiyemi, J Cade… - 2022 - cabidigitallibrary.org
Objectives: Long-acting formulations of cabotegravir (CAB) and rilpivirine (RPV) have
demonstrated efficacy in Phase 3 studies. POLAR (NCT03639311) assessed antiviral …

Long-acting cabotegravir and rilpivirine for HIV-1 suppression: switch to 2-monthly dosing after 5 years of daily oral therapy

A Mills, GJ Richmond, C Newman… - AIDS (London …, 2022 - pubmed.ncbi.nlm.nih.gov
Objectives Long-acting formulations of cabotegravir (CAB) and rilpivirine (RPV) have
demonstrated efficacy in Phase 3 studies. POLAR (NCT03639311) assessed antiviral …
[HTML] nih.gov

[HTML][HTML] Long-acting cabotegravir and rilpivirine for HIV-1 suppression: switch to 2-monthly dosing after 5 years of daily oral therapy

A Mills, GJ Richmond, C Newman… - AIDS (London …, 2022 - ncbi.nlm.nih.gov
Objectives: Long-acting formulations of cabotegravir (CAB) and rilpivirine (RPV) have
demonstrated efficacy in Phase 3 studies. POLAR (NCT03639311) assessed antiviral …
[HTML] lww.com

[HTML][HTML] Long-acting cabotegravir and rilpivirine for HIV-1 suppression: switch to 2-monthly dosing after 5 years of daily oral therapy

A Mills, GJ Richmond, C Newman, O Osiyemi, J Cade… - AIDS, 2022 - journals.lww.com
Objectives: Long-acting formulations of cabotegravir (CAB) and rilpivirine (RPV) have
demonstrated efficacy in Phase 3 studies. POLAR (NCT03639311) assessed antiviral …

Long-acting cabotegravir and rilpivirine for HIV-1 suppression: switch to 2-monthly dosing after 5 years of daily oral therapy

A Mills, GJ Richmond, C Newman, O Osiyemi, J Cade… - AIDS, 2022 - ingentaconnect.com
Objectives: Long-acting formulations of cabotegravir (CAB) and rilpivirine (RPV) have
demonstrated efficacy in Phase 3 studies. POLAR (NCT03639311) assessed antiviral …

Long-acting cabotegravir and rilpivirine for HIV-1 suppression: switch to 2-monthly dosing after 5 years of daily oral therapy.

A Mills, GJ Richmond, C Newman, O Osiyemi… - AIDS (London …, 2022 - europepmc.org
Objectives Long-acting formulations of cabotegravir (CAB) and rilpivirine (RPV) have
demonstrated efficacy in Phase 3 studies. POLAR (NCT03639311) assessed antiviral …

Long-acting cabotegravir and rilpivirine for HIV-1 suppression: switch to 2-monthly dosing after 5 years of daily oral therapy

A Mills, GJ Richmond, C Newman, O Osiyemi, J Cade… - AIDS, 2021 - cir.nii.ac.jp
抄録< jats: sec>< jats: title> Objectives:</jats: title>< jats: p> Long-acting formulations of
cabotegravir (CAB) and rilpivirine (RPV) have demonstrated efficacy in Phase 3 studies …

Long-acting cabotegravir and rilpivirine for HIV-1 suppression: switch to 2-monthly dosing after 5 years of daily oral therapy

A Mills, GJ Richmond, C Newman, O Osiyemi… - AIDS, 2022 - augusta.elsevierpure.com
Objectives: Long-acting formulations of cabotegravir (CAB) and rilpivirine (RPV) have
demonstrated efficacy in Phase 3 studies. POLAR (NCT03639311) assessed antiviral …